
Aakash Desai/LinkedIn
May 30, 2025, 12:32
ASCO25 Update: Aakash Desai Highlights Rapid Evolution of ADCs in Lung Cancer
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on X:
“ASCO25: ADCs in Lung Cancer Rapid Evolution with a robust lineup of ADC trials across 1L, 2L, and neoadjuvant NSCLC and SCLC settings.
Key Targets: TROP2, c-MET, HER3, B7H3
Payloads: TOPOi, TUBi,
Settings: EGFRm, MET overexpressed, chemo-refractory
Highlights:
– EVOKE-01, HERTHENA, TROPION, OptiTROP
– LUMINOSITY, TeliMETCurated table
What did I miss? And what are you guys most excited about?”
More posts featuring ASCO 2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 30, 2025, 13:19
May 30, 2025, 12:53
May 30, 2025, 12:46
May 30, 2025, 12:32
May 30, 2025, 09:10